Study Evaluating Renal Cell Carcinoma Risk Factors (MICRA)

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: June 22, 2009
Last updated: November 4, 2011
Last verified: November 2011

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.

Condition Intervention
Carcinoma, Renal Cell
Other: Epidemiological study according to clinical practice

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Response rate. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Overall survival. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Whole blood

Enrollment: 145
Study Start Date: May 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1 Other: Epidemiological study according to clinical practice
Epidemiological study according to clinical practice.

Detailed Description:

invitation to volunteer


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Treatment naive patients with proven advanced RCC


Inclusion Criteria:

  • Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
  • =18 years, any gender.
  • Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion Criteria:

  • Patients who have already initiated any kind of specific therapy for the treatment of RCC.2.
  • Patients with other neoplasias different from RCC (current or past).
  Contacts and Locations
Please refer to this study by its identifier: NCT00927043

Pfizer Investigational Site
Pamplona, Navarra, Spain, 31008
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT00927043     History of Changes
Other Study ID Numbers: 3066K1-4433, B1771010
Study First Received: June 22, 2009
Last Updated: November 4, 2011
Health Authority: Spain: Comite de Investigacion Clinica

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases processed this record on April 17, 2014